RP MANAGEMENT LLC
Q2 2022 Form 13-F
NEW YORK, NEW YORK
CIK 0001507673
· CRD 161569
· SEC-registered investment adviser
Consolidated report · includes
1 manager
since Q3 2019
$253.2M Reported Value Total
RP MANAGEMENT, LLC reports 19 total accounts under management (AUM). There are 19 discretionary accounts valued at $17,710,040,913, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
20 funds
· $10.8B gross asset value
Private Equity Fund: $9.6B · Hedge Fund: $1.2B
Source: Form ADV filed 2026-03-31
Reported value
$253.2M
Quarter over quarter
+8.0%
Holdings
4
Top-10 concentration
100.0%
Filing Structure
Reports holdings for
- Legorreta Pablo G · File #028-19630 · since Q3 2019 · declared by one filing
Key People
Form ADV owners & control persons
Pablo Gerardo Legorreta
MEMBER
Carolyn Judith Rubin
CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2022 13F record
Q2 2022 13F filing summary
| Period of report | June 30, 2022 |
|---|---|
| Filed | August 10, 2022 |
| Form | 13F-HR |
| Reported value | $253.2M |
| Positions | 4 |
| Change in reported value | +3.0% |
| New positions | 0 |
| Exited positions | 0 |
| Position turnover | 0.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q1 2025 13F
Filed May 2, 2025
|
4 | $138.8M |
|
Q4 2024 13F
Filed Feb 3, 2025
|
4 | $227.7M |
|
Q3 2024 13F
Filed Nov 13, 2024
|
4 | $227.7M |
|
Q2 2024 13F
Filed Aug 13, 2024
|
4 | $178.8M |
|
Q1 2024 13F
Filed May 8, 2024
|
3 | $180.1M |
|
Q4 2023 13F
Filed Feb 13, 2024
|
3 | $148.7M |
|
Q3 2023 13F
Filed Nov 13, 2023
|
3 | $103.6M |
|
Q2 2023 13F
Filed Aug 11, 2023
|
3 | $97.3M |
|
Q1 2023 13F
Filed May 15, 2023
|
3 | $72.2M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
3 | $84.9M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
3 | $216.4M |
|
Q2 2022 13F
Filed Aug 10, 2022
|
4 | $253.2M |
|
Q1 2022 13F
Filed May 11, 2022
|
4 | $245.9M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
4 | $238.9M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
3 | $214.3M |
|
Q2 2021 13F
Filed Aug 12, 2021
|
3 | $205.1M |
|
Q1 2021 13F
Filed May 17, 2021
|
4 | $266.4M |
|
Q4 2020 13F
Filed Feb 16, 2021
|
4 | $326.0M |
|
Q3 2020 13F
Filed Nov 12, 2020
|
5 | $667.3M |
|
Q2 2020 13F
Filed Aug 14, 2020
|
5 | $517.4M |
6 earlier quarters on file — choose one from the quarter menu above.
Top 5 holdings · Q2 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | BHVN BIOHAVEN PHARMACTL HLDG CO L | $161.9M | 63.94% |
| 2 | EPZM EPIZYME INC | $46.8M | 18.49% |
| 3 | BCRX BIOCRYST PHARMACEUTICALS INC | $40.7M | 16.07% |
| 4 | EPZM C EPIZYME INC | $3.8M | 1.5% |
| 5 | VIRX VIRACTA THERAPEUTICS INC | $18.0K | < 0.01% |
Values as reported on the Q2 2022 Form 13F. Every position is in the holdings table below.